These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 30368223

  • 1. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
    Rejdak K, Stelmasiak Z, Grieb P.
    Mult Scler Relat Disord; 2019 Jan; 27():117-120. PubMed ID: 30368223
    [Abstract] [Full Text] [Related]

  • 2. Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis.
    Koch M, Heersema D, Mostert J, Teelken A, De Keyser J.
    Eur J Neurol; 2007 Jul; 14(7):797-800. PubMed ID: 17594338
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 5. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY study group.
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Oligoclonal restriction of antiviral immunoreaction in oligoclonal band-negative MS patients.
    Stich O, Kluge J, Speck J, Rauer S.
    Acta Neurol Scand; 2015 Jun; 131(6):381-8. PubMed ID: 25402869
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 10. Correlation of the IgG index and oligoclonal bands in the cerebrospinal fluid of patients with multiple sclerosis.
    Mares J, Herzig R, Urbanek K, Sladkova V, Sklenarova J, Bekarek V, Schneiderka P, Zapletalova J, Kanovsky P.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):247-9. PubMed ID: 19219215
    [Abstract] [Full Text] [Related]

  • 11. [Clinical characteristics and neurophysiologic findings in patients with multiple sclerosis without oligoclonal IgG in cerebrospinal fluid].
    Mesaros S, Drulović J, Lević Z.
    Srp Arh Celok Lek; 2003 Dec; 131(3-4):122-6. PubMed ID: 14608874
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Magnetic resonance findings in the brain of patients with multiple sclerosis without oligoclonal bands in the cerebrospinal fluid].
    Mesaroc S, Drulović J, Lević Z, Perić V.
    Srp Arh Celok Lek; 2003 Dec; 131(1-2):31-5. PubMed ID: 14608859
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.